Michael Berger
@MFBerger1
Followers
2K
Following
1K
Media
23
Statuses
137
Cancer scientist studying clinical cancer genomics and computational biology @MSKCancerCenter. Comments and opinions are my own.
New York, NY
Joined February 2012
Congratulations to the MSK-IMPACT team at MSK for receiving the American Association for Cancer Research (AACR) Team Science Award. The team, led by @MFBerger1, @DSolit, and @MLadanyi, is recognized for its pivotal advances in clinical genomic sequencing that have transformed
4
21
106
⬇️ Can’t think of a more innovative, impactful, and incredible example of Team Science! Congrats to the @MSKCancerCenter IMPACT team! 👏👏 @MFBerger1 @DSolit @MLadanyi + many more team members! #AACR25 @AACR
Congratulations to the MSK-IMPACT team at MSK for receiving the American Association for Cancer Research (AACR) Team Science Award. The team, led by @MFBerger1 and @DSolit, is recognized for its pivotal advances in clinical genomic sequencing that have transformed oncology
0
5
28
.@MFBerger1, @DSolit, @MLadanyi, and the MSK-Impact team accept the @AACR Team Science Award for developing and implementing a groundbreaking next-generation sequencing platform which has enabled the comprehensive molecular characterization of over 125,000 tumors. #AACR25
4
24
121
Congratulations to @MSKCancerCenter MSK-IMPACT team and @OncoKB for receiving the #AACR25 TEAM Science Award! The impact of this team, assay & data to our understanding of cancer biology is unprecedented.
2
15
84
Things I wish more people knew about doing science in the US (thread):
15
267
698
So happy to finally share this work! Thank you @AnnaVarghese4 @chaiband @EileenMOReilly @MFBerger1 @nikolausschultz for all of your guidance & insight 🧬 Research Briefing:
nature.com
Nature Medicine - KRAS mutations are ubiquitous in pancreatic adenocarcinomas (PDACs) and are associated with poor outcomes. We leveraged a cohort of 2,336 PDAC tumors to characterize genomic...
Excited to share our latest in @NatureMedicine✨ We present a detailed clinico-genomic landscape of pancreatic adenocarcinomas With important implications for RAS 🎯 therapies Expertly co-led by @AnnaVarghese4 and @MariaAPerry. w/@EileenMOReilly & colleagues @MSKCancerCenter
0
4
12
Excited to share our latest in @NatureMedicine✨ We present a detailed clinico-genomic landscape of pancreatic adenocarcinomas With important implications for RAS 🎯 therapies Expertly co-led by @AnnaVarghese4 and @MariaAPerry. w/@EileenMOReilly & colleagues @MSKCancerCenter
6
54
141
Thrilled to share our recent work in @CellCellPress ✨ We study the extent to which tumor suppressor genes in cancer adhere to Knudson's ‘two-hit’ hypothesis, and their clinical implications. 🧵👇 Also a detailed 🧵 by @EdReznik below: @MSKPathology @MSKCancerCenter
A culmination of ~5 years of work, today our work on biallelic alterations across tumor suppressor genes is published in @CellCellPress. With Mark Zucker, Maria Perry, and Chai Bandlamudi
2
10
21
🚀 We are extremely proud to announce the launch of MSK-ACCESS® powered with SOPHiA DDM™! We want to warmly thank everyone who joined our launch event in Switzerland and contributed to make this insightful gathering a success! #oncology #MSKACCESS #MSK #cancerresearch #AI
0
5
7
Great to meet @kanikaarora316 yesterday at #AACR24 - her work was featured in the @AACR Journals collection on Cancer Disparities!
Attending today's #AACR24 session on Genetic Ancestry? ICYMI in @CD_AACR: Genetic Ancestry Correlates with Somatic Differences in a Real-World Clinical Cancer Sequencing Cohort @kanikaarora316 @MFBerger1
https://t.co/TK22ZyouJV
@MSKCancerCenter
1
6
17
Now online in @CD_AACR: #DeepLearning Model for Tumor Type Prediction using Targeted Clinical Genomic Sequencing Data @mmdarmofal @MFBerger1 @quaidmorris
https://t.co/dVGKB0bIfp
@MSKCancerCenter
0
12
58
Packed house at #AMPath23 to see 🌟 lead scientist @CDebyaniPhD present @OncoKB, the @US_FDA recognized cancer knowledge base, bringing precision oncology to patients at @MSKCancerCenter and now around the 🌏
0
14
43
Precision Cancer Drugs Glitter with Promise--If You Can Get Them https://t.co/5cLUunoWeB via @sciam
scientificamerican.com
A growing arsenal of genetically tailored oncology treatments have spectacular results, but scope and access remain limited
0
8
19
As promised here's a quick tweetorial for our @CD_AACR article: Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer https://t.co/aQOFeN76db 👇👇👇
4
16
31
Yesterday, President Biden announced my appointment as a White House Fellow https://t.co/lUBPDLmF7g As the first oncologist ever selected, I'm excited to lead, serve, and innovate for our patients in this new role with the Cancer Moonshot and Health Outcomes teams @WHOSTP
40
5
169
Treatment options are limited for the 3-5% of patients who have cancers of unknown primary. So, we are excited to present 💥GDD-ENS💥: a highly accurate, comprehensive tumor type classifier based on data from a routinely applied FDA-authorized test 🧵 https://t.co/uYOyZ1LuqD
0
3
23
Hard to believe it has been 25 yrs @MSKCancerCenter. Thanks to my mentors, colleagues, mentees, patients and family who have taught and supported me along the way. Seems like a good time to look back at progress made in cancer research and treatment and hopes for the future. 1/x
16
25
412
Deeply appreciative of everyone who helped develop #MSKimpact, #MSKaccess, #MPath, @OncoKB, @cbioportal, and of the physicians, scientists, nurses, administrators, clinic staff, couriers & accessioners who deliver precision diagnostics day after day. @MSKPathology @MskccCMO
How 2 MSK-developed #cancer #genetictests - MSK-IMPACT® (which uses a tissue biopsy to identify the best treatment) & MSK-ACCESS® (a blood test to detect a patient's response to treatment) - have helped revolutionize the way cancer is treated worldwide: https://t.co/V4ml1fDJe9
0
9
60
Pivotal research by @MSKCancerCenter's Sarat Chandarlapaty, MD, PhD, contributed to the recent approval of Elacestrant for people w/ advanced or metastatic ESR1-mutant #breastcancer. Congrats to all who made this incredible advance possible! #bcsm
https://t.co/DgV80b5mSu
mskcc.org
Learn how an MSK lab discovery in 2013 paved the way for the approval of a new breast cancer drug 10 years later.
0
6
37
Thanks to all who stopped by my poster today - feeling very inspired at my first in person AACR! #AACR2023
Great science by @mmdarmofal (#5440) and @MeelisXY (#5214) at the #AACR23 poster session, presenting novel insights from #MSKimpact tumor sequencing data. 💪🧬
0
3
24